Compare · PRKS vs SLNO
PRKS vs SLNO
Side-by-side comparison of United Parks & Resorts Inc. (PRKS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRKS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 1.3x PRKS ($2.16B).
- Over the past year, PRKS is down 6.1% and SLNO is down 39.2% - PRKS leads by 33.1 points.
- PRKS has been more active in the news (12 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 8 for PRKS).
- Company
- United Parks & Resorts Inc.
- Soleno Therapeutics Inc.
- Price
- $45.04-4.17%
- $53.02+0.08%
- Market cap
- $2.16B
- $2.76B
- 1M return
- -2.01%
- +0.76%
- 1Y return
- -6.14%
- -39.20%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2014
- News (4w)
- 12
- 1
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Northcoast initiated coverage on United Parks & Resorts Inc.
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 1,821 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 1,821 shares (SEC Form 4)
- Director Chambers James P. was granted 1,098 shares, increasing direct ownership by 2% to 65,558 units (SEC Form 4)
- Director Gray William was granted 1,258 shares, increasing direct ownership by 2% to 76,721 units (SEC Form 4)
- Director Hartnett Timothy was granted 1,821 shares, increasing direct ownership by 2% to 81,378 units (SEC Form 4)
- Director Lipman Nathaniel was granted 207 shares, increasing direct ownership by 1% to 20,316 units (SEC Form 4)
- Director Schaefer Kimberly was granted 415 shares, increasing direct ownership by 0.98% to 42,740 units (SEC Form 4)
- Director Narang Neha Jogani was granted 830 shares, increasing direct ownership by 1% to 57,376 units (SEC Form 4)
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)